The PURPOSE efficacy trials are expected to report results later this year or in early 2025. If the six-monthly injectable lenacapavir demonstrates safety and efficacy, it will be the next long-acting injectable PrEP option to enter the market—and it is not too early to plan. Excerpted from PxWire.
Was this content helpful?
Tell us how we can improve the content.
Was this content helpful?
Thank you for your feedback!